NCT02716974 - A Study of Definitive Therapy to Treat Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2022

Conditions

Prostate Cancer

Interventions

DRUG

Leuprolide Acetate

22.5mg by intramuscular (IM) injection every 3 months

DRUG

Bicalutamide

bicalutamide (Casodex) 50mg by mouth daily

DRUG

Docetaxel

Docetaxel (taxotere) 75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles.

PROCEDURE

Prostatectomy

Removal of the entire prostate gland, plus some surrounding tissue.

RADIATION

Radiation

5 high dose radiation treatments to the metastatic (tumor has spread to other parts of the body) sites.

Trial Locations (3)

Sibley Memorial Hospital, Washington D.C.

Johns Hopkins School of Medicine - Sidney Kimmel Comprehensive Cancer Center, Baltimore

Johns Hopkins Bayview Medical Center, Baltimore

All Listed Sponsors

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER